Swiss biotechnology company Lonza Group AG (Lonxa) (SWX: LONN) has agreed with British pharmaceutical company AstraZeneca Plc (STO: AZN) (LON: AZN) to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, Reuters news agency reported on Friday.
According to Lonxa, AZD7442 is in Phase I clinical studies and AstraZeneca plans to advance the combination into Phase III trials in the coming weeks.
Lonza will manufacture drug substance for AZD7442 at its facilities in the US.
These operations are expected to commence in the first half of 2021.
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
SciBase technology selected as primary endpoint in NIH-led skin exposure study
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose